Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$2.48 - $9.01
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Latest price
Market Cap | $1.10B |
EV | $1.06B |
Shares Outstanding | 148.58M |
Beta | 1.73 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $9.71 |
P/E 2025E | - |
P/Revenue 2025E | 5.16x |
Revenue | 5.10% |
EPS | 11.60% |
Operating Cash Flow | 21.00% |
Free Cash Flow | 27.00% |
Revenue | 21.30% |
EPS | 23.40% |
Operating Cash Flow | 36.00% |
Free Cash Flow | - |
Gross Margin 2025E | 60.78% |
Net Profit Margin 2025E | -64.43% |
ROE 2025E | -94.32% |
ROCE 2024 | -62.41% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Adaptive Biotechnologies Corporation
ADPT
Sector
Healthcare
Industry
Biotechnology
CEO
Robins, Chad
Employees
619
Website
www.adaptivebiotech.comIPO Date
2019-06-27
Headquarters
1165 Eastlake Avenue East, Seattle, Washington, 98109, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved